AUA 2022 quantitative piflufolastat F18 PSMA scan indices as a response imaging-biomarker to androgen deprivation therapy in veterans with newly diagnosed metastatic prostate cancer.
Shreeya Popat, Jennifer Chyu, and Una Lee discuss the overlooked impact of mesh sling complications on the partners of urologic patients. Their research, focusing on…
Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the…
Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis and Sarah Wood. Dr. Davis describes the…
At the 2024 UCSF-UCLA PSMA Conference, Carlos Uribe emphasizes the critical role of dosimetry in enhancing the precision and personalization of radiopharmaceutical therapies (RPTs), detailing…
Steven Patierno delves into his 25-year journey tackling cancer disparities, with a focus on prostate cancer. Beginning in Washington D.C., Dr. Patierno’s work highlighted the…
Kriti Mittal and Guru Sonpavde discuss advancements in the treatment of non-muscle invasive bladder cancer. Dr. Mittal highlights the FDA’s 2020 approval of pembrolizumab for…
Rashid Sayyid and Zach Klaassen discuss the AUA’s updated guidelines for surgical therapy of BPH-related lower urinary tract symptoms. They recommend surgery for patients with…
Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer,…
prostate cancer, Gallium-68 based radiotracer, [68Ga]Ga-PSMA-11, [18F]PSMA-1007, [18F]DCFPyL, [18F]JK-PSMA-7, [18F]rhPSMA-7, [18F]AlF-PSMA-11, staging of prostate cancer,
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight…
